Fiduciary Management Inc. WI Sells 358,652 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• Fiduciary Management Inc. WI decreased its stake in Fresenius Medical Care AG & Co. KGaA by 5.7%, ending the first quarter with approximately 5.95 million shares valued at $148.2 million.
• Recent analyst evaluations show a shift in sentiment with Zacks Research downgrading the company from a "strong-buy" to a "hold" rating amidst several other mixed reviews.
• The company reported earnings of $0.52 per share, exceeding expectations, with quarterly revenues reaching $5.54 billion, significantly above forecasts of $5 billion.

Fiduciary Management Inc. WI decreased its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 5.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,950,011 shares of the company's stock after selling 358,652 shares during the period. Fiduciary Management Inc. WI owned approximately 1.01% of Fresenius Medical Care AG & Co. KGaA worth $148,155,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 34.0% in the first quarter. GAMMA Investing LLC now owns 9,603 shares of the company's stock worth $239,000 after purchasing an additional 2,439 shares during the period. Cerity Partners LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 22.4% in the first quarter. Cerity Partners LLC now owns 39,903 shares of the company's stock worth $994,000 after acquiring an additional 7,299 shares during the period. Jane Street Group LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at approximately $447,000. Point72 Asset Management L.P. bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $850,000. Finally, Forum Financial Management LP bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $247,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on FMS shares. Truist Financial boosted their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Monday, May 12th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 18th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "strong-buy" rating in a research note on Friday. Finally, Morgan Stanley reissued an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of "Hold" and an average target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.2%

Shares of FMS stock traded up $0.3150 on Friday, hitting $25.5750. The stock had a trading volume of 271,625 shares, compared to its average volume of 328,600. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44. The business has a 50 day moving average price of $26.41 and a 200 day moving average price of $25.82. Fresenius Medical Care AG & Co. KGaA has a one year low of $18.94 and a one year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The firm had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $5 billion. On average, research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.